Literature DB >> 16698591

Surgical therapy for hiliar cholangiocarcinoma: analysis of 198 cases.

Bai-He Zhang1, Qing-Bao Cheng, Xiang-Ji Luo, Yong-Jie Zhang, Xiao-Qing Jiang, Bao-Hua Zhang, Bin Yi, Wen-Long Yu, Meng-Chao Wu.   

Abstract

BACKGROUND: Carcinoma of the hepatic duct confluence is the most common site of bile duct malignancies. Although hilar cholangiocarcinoma has been characterized as a slow-growing and late metastasizing tumor, post-therapeutic prognosis has remained poor. The study was undertaken to analyze factors influencing the surgical curative effect of hilar cholangiocarcinoma.
METHODS: A retrospective clinical analysis was made of 198 patients with hilar cholangiocarcinoma who had been surgically treated at our hospital from 1997 to 2002. Jaundice (94.5%, 187 patients), pruritus (56.6%, 112) and abdominal pain (33.8%, 67) were the main symptoms. According to the Bismuth-Corlette classification, there were 14 type I patients, 19 type II patients, 12 type IIIa patients, 15 type IIIb patients, 112 type IV patients, and 26 unclassified patients. 144 patients received laparotomy, and 120 tumor resection including radical resection (59 patients) and palliative resection (61). Fifty-four patients were treated by endoscopic surgery and 16 patients by postoperative adjuvant radiation.
RESULTS: Occupation, preoperative level of total serum bilirubin, operative procedure and postoperative adjuvant radiation affected postoperative survival of the patients. The postoperative survivals of endoscopic nose-biliary drainage (ENBD) group, endoscopic retrograde biliary drainage (ERBD) or endoscopic metal biliary endoprosthesis (EMBE) group, biliary exploration and drainage group, palliative resection group and radical resection group differed (chi2=87.0489, P<0.01).
CONCLUSION: Early diagnosis and radical resection are important to improve the prognosis of hilar cholangiocarcinoma.

Entities:  

Mesh:

Year:  2006        PMID: 16698591

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  6 in total

1.  Prognostic factors in patients with advanced cholangiocarcinoma: role of surgery, chemotherapy and body mass index.

Authors:  Mirna H Farhat; Ali I Shamseddine; Ayman N Tawil; Ghina Berjawi; Charif Sidani; Wael Shamseddeen; Kassem A Barada
Journal:  World J Gastroenterol       Date:  2008-05-28       Impact factor: 5.742

Review 2.  Palliation: Hilar cholangiocarcinoma.

Authors:  Mahesh Kr Goenka; Usha Goenka
Journal:  World J Hepatol       Date:  2014-08-27

3.  Roles of the MEK1/2 and AKT pathways in CXCL12/CXCR4 induced cholangiocarcinoma cell invasion.

Authors:  Kawin Leelawat; Surang Leelawat; Siriluck Narong; Suradej Hongeng
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

4.  Guidelines for palliative surgery of cholangiocarcinoma.

Authors:  H Witzigmann; H Lang; H Lauer
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

5.  Characterization of two novel cell lines with distinct heterogeneity derived from a single human bile duct carcinoma.

Authors:  Jinghan Wang; Linfang Li; Keqiang Zhang; Yong Yu; Bin Li; Jiang Li; Zi Yan; Zhenli Hu; Yun Yen; Mengchao Wu; Xiaoqing Jiang; Qijun Qian
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

6.  The Role of Portoenterostomy with Aggressive Hilar Dissection in Biliary Tract Tumors: Report of Case Series and Review of the Literature.

Authors:  Osman Nuri Dilek; Feyyaz Güngör; Turan Acar; Arif Atay; Şebnem Karasu; Halis Bağ; Fatma Hüsniye Dilek
Journal:  Indian J Surg       Date:  2020-05-12       Impact factor: 0.656

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.